10,659 Shares in Arcellx, Inc. (NASDAQ:ACLX) Purchased by Walleye Capital LLC

Walleye Capital LLC acquired a new position in shares of Arcellx, Inc. (NASDAQ:ACLX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,659 shares of the company's stock, valued at approximately $817,000.

Other large investors have also bought and sold shares of the company. Headlands Technologies LLC bought a new position in Arcellx in the 4th quarter worth approximately $41,000. KBC Group NV raised its position in shares of Arcellx by 37.3% during the fourth quarter. KBC Group NV now owns 1,388 shares of the company's stock worth $106,000 after acquiring an additional 377 shares during the last quarter. Avanza Fonder AB acquired a new position in shares of Arcellx during the fourth quarter valued at $184,000. Kazazian Asset Management LLC acquired a new stake in Arcellx in the fourth quarter worth about $204,000. Finally, Landscape Capital Management L.L.C. bought a new stake in Arcellx during the 4th quarter worth about $214,000. 96.03% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Arcellx

In related news, insider Rami Elghandour sold 38,300 shares of the firm's stock in a transaction on Wednesday, February 26th. The shares were sold at an average price of $62.02, for a total transaction of $2,375,366.00. Following the sale, the insider now directly owns 149,186 shares in the company, valued at $9,252,515.72. This trade represents a 20.43 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Kavita Patel sold 1,500 shares of the company's stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $64.57, for a total transaction of $96,855.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 54,455 shares of company stock valued at $3,408,458. Corporate insiders own 6.24% of the company's stock.

Arcellx Trading Up 0.5 %

Shares of NASDAQ:ACLX traded up $0.34 during trading on Thursday, hitting $63.97. 441,870 shares of the company's stock were exchanged, compared to its average volume of 556,682. The firm has a market cap of $3.51 billion, a P/E ratio of -90.10 and a beta of 0.33. The firm has a 50-day moving average price of $64.80 and a two-hundred day moving average price of $74.96. Arcellx, Inc. has a 1-year low of $47.88 and a 1-year high of $107.37.

Arcellx (NASDAQ:ACLX - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.24). The company had revenue of $15.27 million for the quarter, compared to the consensus estimate of $27.42 million. Arcellx had a negative return on equity of 8.28% and a negative net margin of 25.94%. As a group, research analysts predict that Arcellx, Inc. will post -1.58 EPS for the current year.

Arcellx Profile

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).